174 related articles for article (PubMed ID: 38134061)
1. Multimodal MRI-based radiomic nomogram for predicting telomerase reverse transcriptase promoter mutation in IDH-wildtype histological lower-grade gliomas.
Huo X; Wang Y; Ma S; Zhu S; Wang K; Ji Q; Chen F; Wang L; Wu Z; Li W
Medicine (Baltimore); 2023 Dec; 102(51):e36581. PubMed ID: 38134061
[TBL] [Abstract][Full Text] [Related]
2. Telomerase reverse transcriptase promoter mutation and histologic grade in IDH wild-type histological lower-grade gliomas: The value of perfusion-weighted image, diffusion-weighted image, and
Ikeda S; Sakata A; Fushimi Y; Okuchi S; Arakawa Y; Makino Y; Mineharu Y; Nakajima S; Hinoda T; Yoshida K; Miyamoto S; Nakamoto Y
Eur J Radiol; 2023 Feb; 159():110658. PubMed ID: 36571926
[TBL] [Abstract][Full Text] [Related]
3. Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status.
Park YW; Kim S; Park CJ; Ahn SS; Han K; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2022 Dec; 32(12):8089-8098. PubMed ID: 35763095
[TBL] [Abstract][Full Text] [Related]
4. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
[TBL] [Abstract][Full Text] [Related]
5. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [
Li Z; Kaiser L; Holzgreve A; Ruf VC; Suchorska B; Wenter V; Quach S; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4415-4425. PubMed ID: 34490493
[TBL] [Abstract][Full Text] [Related]
6. Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas.
Pei D; Guan F; Hong X; Liu Z; Wang W; Qiu Y; Duan W; Wang M; Sun C; Wang W; Wang X; Guo Y; Wang Z; Liu Z; Xing A; Guo Z; Luo L; Liu X; Cheng J; Zhang B; Zhang Z; Yan J
Eur Radiol; 2023 May; 33(5):3455-3466. PubMed ID: 36853347
[TBL] [Abstract][Full Text] [Related]
7. A nomogram strategy for identifying the subclassification of IDH mutation and ATRX expression loss in lower-grade gliomas.
Wu S; Zhang X; Rui W; Sheng Y; Yu Y; Zhang Y; Yao Z; Qiu T; Ren Y
Eur Radiol; 2022 May; 32(5):3187-3198. PubMed ID: 35133485
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners.
Zhou W; Wen J; Huang Q; Zeng Y; Zhou Z; Zhu Y; Chen L; Guan Y; Xie F; Zhuang D; Hua T
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1423-1435. PubMed ID: 38110710
[TBL] [Abstract][Full Text] [Related]
9. Conventional magnetic resonance imaging-based radiomic signature predicts telomerase reverse transcriptase promoter mutation status in grade II and III gliomas.
Jiang C; Kong Z; Zhang Y; Liu S; Liu Z; Chen W; Liu P; Liu D; Wang Y; Lyu Y; Zhao D; Wang Y; You H; Feng F; Ma W
Neuroradiology; 2020 Jul; 62(7):803-813. PubMed ID: 32239241
[TBL] [Abstract][Full Text] [Related]
10. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
[TBL] [Abstract][Full Text] [Related]
11. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
Park CJ; Han K; Kim H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK
Eur Radiol; 2020 Dec; 30(12):6464-6474. PubMed ID: 32740813
[TBL] [Abstract][Full Text] [Related]
12. Sub-region based radiomics analysis for prediction of isocitrate dehydrogenase and telomerase reverse transcriptase promoter mutations in diffuse gliomas.
Zhang H; Ouyang Y; Zhang H; Zhang Y; Su R; Zhou B; Yang W; Lei Y; Huang B
Clin Radiol; 2024 May; 79(5):e682-e691. PubMed ID: 38402087
[TBL] [Abstract][Full Text] [Related]
13. Radiomic study on preoperative multi-modal magnetic resonance images identifies IDH-mutant TERT promoter-mutant gliomas.
Wang H; Zhang S; Xing X; Yue Q; Feng W; Chen S; Zhang J; Xie D; Chen N; Liu Y
Cancer Med; 2023 Feb; 12(3):2524-2537. PubMed ID: 36176070
[TBL] [Abstract][Full Text] [Related]
14. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW
Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
[TBL] [Abstract][Full Text] [Related]
17. Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations.
Izquierdo C; Barritault M; Poncet D; Cartalat S; Joubert B; Bruna J; Jouanneau E; Guyotat J; Vasiljevic A; Fenouil T; Berthezène Y; Honnorat J; Meyronet D; Ducray F
Neurosurgery; 2019 Sep; 85(3):E448-E456. PubMed ID: 30407589
[TBL] [Abstract][Full Text] [Related]
18. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
[TBL] [Abstract][Full Text] [Related]
19. Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature.
Li Y; Liu X; Qian Z; Sun Z; Xu K; Wang K; Fan X; Zhang Z; Li S; Wang Y; Jiang T
Eur Radiol; 2018 Jul; 28(7):2960-2968. PubMed ID: 29404769
[TBL] [Abstract][Full Text] [Related]
20. Machine learning and radiomic phenotyping of lower grade gliomas: improving survival prediction.
Choi YS; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Jain R; Lee SK
Eur Radiol; 2020 Jul; 30(7):3834-3842. PubMed ID: 32162004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
